CD8+ T cells are crucial for antitumor immunity. However, their functionality is often altered in higher-risk myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). To understand their role in disease progression, we conducted a comprehensive immunophenotypic analysis of 104 pretreatment bone marrow (BM) samples using mass and flow cytometry. Our findings revealed an increased frequency of CD57+CXCR3+ subset of CD8+ T cells in patients who did not respond to azacitidine (AZA) therapy. Furthermore, an increased baseline frequency (>29%) of the CD57+CXCR3+CD8+ T-cell subset was correlated with poor overall survival. We performed single-cell RNA sequencing to assess the transcriptional profile of BM CD8+ T cells from treatment-naïve patients. The response to AZA was linked to an enrichment of IFN-mediated pathways, whereas nonresponders exhibited a heightened TGF-β signaling signature. These findings suggest that combining AZA with TGF-β signaling inhibitors targeting CD8+ T cells could be a promising therapeutic strategy for patients with higher-risk MDS and AML. Significance: Immunophenotypic analysis identified a BM CD57+CXCR3+ subset of CD8+ T cells associated with response to AZA in patients with MDS and AML. Single-cell RNA sequencing analysis revealed that IFN signaling is linked to the response to treatment, whereas TGF-β signaling is associated with treatment failure, providing insights into new therapeutic approaches.
CD8+ T cells are critical players in anti-tumor immunity against solid tumors, targeted by immunotherapies. Emerging evidence suggests that CD8+ T cells also play a crucial role in anti-tumor responses and determining treatment outcomes in hematologic malignancies like myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). In this review, we focus on the implication of CD8+ T cells in the treatment response of patients with MDS and AML. First, we review reported studies of aberrant functionality and clonality of CD8+ T cells in MDS and AML, often driven by the immunosuppressive bone marrow microenvironment, which can hinder effective antitumor immunity. Additionally, we discuss the potential use of CD8+ T cell subpopulations, including memory and senescent-like subsets, as predictive biomarkers for treatment response to a variety of treatment regimens, such as hypomethylating agents, which is the standard of care for patients with higher-risk MDS, and chemotherapy which is the main treatment of patients with AML. Understanding the multifaceted role of CD8+ T cells and their interaction with malignant cells in MDS and AML will provide useful insights into their potential as prognostic/predictive biomarkers, but also uncover alternative approaches to novel treatment strategies that could reshape the therapeutic landscape, thus improving treatment efficacy, aiding in overcoming treatment resistance and improving patient survival in these challenging myeloid neoplasms.
CD8+ T cells are critical players in anti-tumor immunity against solid tumors, targeted by immunotherapies. Emerging evidence suggests that CD8+ T cells also play a crucial role in anti-tumor responses and determining treatment outcomes in hematologic malignancies like myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). In this review, we focus on the implication of CD8+ T cells in treatment response of patients with MDS and AML. First, we review reported studies of aberrant functionality and clonality of CD8+ T cells in MDS and AML, often driven by the immunosuppressive bone marrow microenvironment, which can hinder effective antitumor immunity. Additionally, we discuss the potential use of CD8+ T cell subpopulations, including memory and senescent-like subsets, as predictive biomarkers for treatment response to a variety of treatment regimens, such as hypomethylating agents which is the standard of care for patients with higher-risk MDS, and chemotherapy which is the main treatment of patients with AML. Understanding the multifaceted role of CD8+ T cells and their interaction with malignant cells in MDS and AML, will provide useful insights into their potential as prognostic/predictive biomarkers, but also uncover alternative approaches to novel treatment strategies that could reshape the therapeutic landscape, thus improving treatment efficacy, aiding in overcoming treatment resistance and improving patient survival in these challenging myeloid neoplasms.
Association between the frequency of CD57+CXCR3+CD8+ T cells and outcome in patients with HR-MDS and AML under treatment with AZA. A, Box plots displaying the percentage of the CD57+CXCR3+ cells within CD8+ T cells, assessed by flow cytometry in responders and nonresponders (HR-MDS, n = 12 responders and 9 nonresponders; AML, n = 9 responders and 11 nonresponders; CMML, n = 5 responders and 5 nonresponders). B, After stratification of patients with HR-MDS and AML to responders (n = 12) and nonresponders (n = 19), FlowSOM analysis was performed on BM CD8+ T cells, which generated six metaclusters that are projected onto the viSNE plots. Representative viSNE plots (one for each group) are shown. C, Box plots showing the proportion of all metaclusters, expressed as the frequency within CD8+ T cells. D, Heatmap depicting the expression levels of all T-related markers. E, Kaplan–Meier curves for OS in patients which received AZA treatment, with ≤29% (n = 51) and >29% (n = 26) CD57+CXCR3+ CD8+ T cells before treatment initiation. The survival curves were compared by the log-rank (Mantel–Cox) test, and the P value is shown. The median OS of the ≤29% group was 20.98 months, whereas the median OS of the >29% group was 12.05 months. F, Survival curves for each disease subgroup. Increased (%) CD57+CXCR3+ correlates significantly with worse survival in patients with HR-MDS and AML, whereas no association is observed in patients with CMML. G, Patients with HR-MDS and AML with ≤29% CD57+CXCR3+ exhibited higher response rates. No association between the frequency of CD57+CXCR3+CD8+ T cells and response to therapy was observed in patients with CMML. An unpaired Student t test was used in A. A Mann–Whitney U test was used in D. **, P < 0.01; ***, P < 0.001.